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TO THE EDITOR
The clinical use of aminoglycoside
antibiotics lies in their antimicrobial
activity due to their ability to inhibit
bacterial translation. However, recent
studies have also shown that aminogly-
cosides have the innate potential to
induce readthrough of nonsense muta-
tions in human cells. Consequently, this
group of antibiotics has been experi-
mentally utilized as potential pharma-
cogenetic agents to reverse the effects
of pathogenic nonsense mutations in
various human genetic disorders. Sev-
eral in vitro and clinical studies gave
promising results (Clancy et al., 2001;
Sleat et al., 2001; Helip-Wooley et al.,
2002; Keeling and Bedwell, 2002;
Wilschanski et al., 2003; Aguiari
et al., 2004; Howard et al., 2004).
Nevertheless, the ability of aminoglyco-
sides to induce readthrough of stop
mutations has not yet been demon-
strated for any of the genodermatoses.
This oversight has occurred in spite of
the fact that the therapeutic concentra-
tion of topical gentamicin, for instance,
is 100-fold higher than that of the
recommended serum concentrations.
Additionally, the usual concern for
aminoglycoside side effects (such as
hearing loss and renal insufficiency) is
generally not an issue during their
topical application as long as the
epidermal basal membrane is intact.
Hailey–Hailey disease (HHD, MIM#
169600) or chronic benign familial
pemphigus is a blistering skin disorder
that has been linked to mutations in the
ATP2C1 gene encoding the human
secretory pathway Ca2þ /Mn2þ ATPase
(hSPCA1) (Hu et al., 2000; Sudbrak
et al., 2000). More than 80 pathogenic
ATP2C1 mutations have been reported
in HHD patients, among which B20%
is a base substitution that causes a
premature stop mutation that results in
the synthesis of a truncated form of
hSPCA1 (Foggia and Hovnanian, 2004).
In this study, we addressed whether
topical aminoglycosides may be bene-
ficial for the treatment of HHD patients
carrying nonsense mutations. Antibio-
tics in general have been among the
treatment repertoire of HHD due to the
observation that dermal infections can
exacerbate the associated rash (Burge,
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Figure 1. Topical gentamicin induces early remission in HHD. The study was conducted according to
the Declaration of Helsinki principles and the medical ethical committee of the University of Pe´cs
approved all described studies. Gentamicin (0.1%) (1 mg/ml) was applied twice topically to a
submammary skin eruption (left column). The effect of this treatment was compared to a topical
preparation containing 5% boric acid and 2% salicylic acid, which has been previously used successfully
in the volunteer patient (right column). The patient carries the already reported 1402C4T mutation of
ATP2C1, leading to a UGA premature stop mutation (R468X) (Hu et al., 2000) (case report under
preparation). The proband reported resolution of constitutional symptoms by day 2 and reached
complete healing of the acute eruption between days 7 and 10 of gentamicin treatment. On the contrary,
the area treated with the boric acid/salicylic acid preparation healed significantly slower with
constitutional symptoms present until days 10–12 of treatment, and possessed small patches of erythema
even by day 18 of therapy.
Abbreviations: HHD, Hailey–Hailey disease; hSPCA1, human secretory pathway Ca2þ /Mn2þ ATPase
1992). Indeed, staphylococci and other
microbes may induce IL-6 expression in
keratinocytes and consequently de-
crease hSPCA1 expression in an auto-
crine fashion; this process has been
implicated in the exacerbation of symp-
toms in HHD (Sasaki et al., 2003;
Mayuzumi et al., 2005). However, prior
to recognizing the genetic background
of HHD, gentamicin has specifically
been found to be part of the optimal
treatment regimen for some patients
(Galimberti et al., 1988). Indeed, we
found that topical gentamicin caused
remission in a volunteer HHD patient
carrying an already reported UGA
nonsense mutation (R468X) (Hu et al.,
2000) more than 10 days earlier than
topical boric acid/salicylic acid therapy
(Figure 1). Boric acid at the adminis-
tered concentration (5%) is bactericidal
against staphylococci and is compar-
able to gentamicin in its efficacy for the
treatment of chronic otitis media (Ben-
son, 1998; Moshi et al., 2000). How-
ever, to our knowledge, boric acid does
not affect readthrough.
As our elderly patient did not con-
sent to a repeat skin biopsy (a diagnos-
tic one has been performed for her
several years before), we decided to test
our new therapeutic approach at the
molecular level in the eukaryotic Sac-
charomyces cerevisiae model of HHD.
ATP2C1 is an ortholog of the yeast
PMR1 gene (Kellermayer, 2005).
hSPCA1 fully complements the pheno-
types of PMR1-defective (pmr1D) yeast
(Ton et al., 2002) and heterologous
expression of mutant ATP2C1 in pmr1D
S. cerevisiae cells has proved to be a
useful screening method to address
consequent functional disturbances of
hSPCA1 (Ton and Rao, 2004). Addi-
tionally, the pmr1D yeast model system
was shown to be valuable in under-
standing the potential pharmacome-
chanisms of therapeutic agents, such
as FK506, for HHD (Szigeti and Keller-
mayer, 2004). Consequently, PMR1-
deficient S. cerevisiae has proved to
be a valuable model organism for
HHD.
We introduced the 1402C4T muta-
tion into ATP2C1 in a yeast expression
plasmid and transformed a pmr1D yeast
strain with the construct. We found that
paromomycin, an aminoglycoside cap-
able of inducing efficient readthrough
in yeast, stimulated growth of the
pmr1D yeast strain expressing
hSPCA1-R468X when compared to the
same yeast strain expressing hSPCA1
with a pathogenic missense mutation
(Figure 2). Furthermore, an increase in
full-length hSPCA1 protein could be
detected by immunoprecipitation of
radiolabelled cell extracts when yeast
pmr1
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Figure 2. Paromomycin promotes the growth of a PMR1-defective yeast strain expressing hSPCA1-
R468X. The pmr1D yeast strain YDB279 (Miseta et al., 1999) is unable to grow in calcium-depleted
growth media (such as media containing the chelating agents EGTA or BAPTA). This phenotype is
complemented by the expression of hSPCA1 and this yeast model system has proved to be useful for
functional testing of ATP2C1 mutations (Ton and Rao, 2004). We introduced the 1402C4T mutation into
a yeast expression plasmid harboring ATP2C1 (a generous gift from Dr Rajini Rao) using the
QuickChange site-directed mutagenesis kit (Stratagene) using primers DB2561 (50-GCT GTT AAG TGT
GTA CAC TGA ACA CAG CAG GAC-30) and DB2562 (50-GTC CTG CTG TGT TCA GTG TAC ACA CTT
AAC AGC-30). The pmr1D yeast strain YDB0279 was transformed with the plasmids expressing wild-type
hSPCA1, hSPCA1-R468X, or hSPCA1-T570I. Growth of the strains was evaluated on yeast minimal media
(SM-URA, 2% dextrose, 40 mM Mes-Tris, pH 6.5) (a) and the same media supplemented with 2 mM EGTA
(b) or 2 mM EGTAþ 50mg/ml paromomycin (c). While only the strain expressing wild-type hSPCA1 could
grow well on 2 mM EGTA, paromomycin stimulated the growth of the pmr1D strain expressing the
hSPCA1-R468X mutant, but not the strain expressing the hSPCA1-T570I mutant. These results suggest
that paromomycin can functionally reverse the effects of the R468X mutation by inducing readthrough of
the UGA nonsense mutation.
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Figure 3. An increase in full-length hSPCA1
protein can be detected in yeast cells grown in the
presence of aminoglycosides. A pmr1D yeast
strain that expressed hSPCA1-R468X was grown in
the presence (þ ) or absence () of paromomycin
for 18 h. Cultures were then metabolically labeled
with Tran 35S-label (ICN Pharmaceuticals) for
40 minutes and cell extracts were immunopreci-
pitated using a rabbit polyclonal antibody to the
carboxyl terminus (amino acids 720–919) of
hSPCA1 (Santa Cruz Biotechnology, Inc.) and
subjected to SDS-PAGE. Immunoprecipitated pro-
teins were visualized by PhosphorImager analysis
(GE Healthcare). While the truncated protein
cannot be detected with this antibody, an increase
in full-length hSPCA1 protein (115 kDa) was
detected in yeast cells harboring the hSPCA1-
R468X plasmid treated with 100 mg/ml paromo-
mycin (þ ) compared to an untreated control strain
(). Besides hSPCA1, we also immunoprecipitated
the beta subunit of the mitochondrial F1-ATPase
beta subunit (indicated as F1b) from lysates of each
strain. This control shows that total protein
synthesis is not significantly increased in the
presence of paromomycin.
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cells carrying a plasmid expressing
hSPCA1-R468X were grown in the
presence of paromomycin (Figure 3).
In conclusion, this study addresses
topical aminoglycoside therapy in a
genodermatosis with the objective of
inducing readthrough of a pathogenic
nonsense mutation. Topical gentamicin
was found to be far more effective in
inducing remission in a HHD patient
carrying a premature stop mutation
than an accepted topical disinfectant.
Observations in a yeast model system of
HHD supported the clinical findings
that topical aminoglycosides may be
beneficial therapeutic agents for pa-
tients harboring ATP2C1 premature
stop mutations. These findings will have
to be addressed in the skin or keratino-
cytes of HHD patients harboring
ATP2C1 nonsense mutations to conclu-
sively show that topical aminoglyco-
sides can induce readthrough of
premature stop mutations in the epi-
dermis. However, our initial clinical
and molecular observations highlight
the potentially great value of topical
aminoglycosides in the treatment of
genodermatoses.
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